what we do
Myriad Life Sciences combines global expertise and local insights to address the most complex issues that today’s healthcare companies face.
We help pharmaceuticals and medical device companies across all stage of development find new opportunities to expand in the region and beyond.
Myriad Life Sciences provides commercially
-focused advisory services to clients across
pharmaceutical and biotech sectors with our
unique blend of experience and capabilities.
Myriad Life Sciences supports clients with
their licensing processes, taking a flexible
approach and leveraging on our commercial
expertise to particular licensing opportunities
Myriad Life Sciences is committed to
invest in exceptional healthcare companies
that will help ensure humanity lives
healthier, longer, and more productive lives.
what we do
We work with our clients to assess commercial opportunity of their portfolio.
Our clinical expertise blended with market insights set the tone for robust and independent valuation services.
Pricing & Reimbursement
We elevate our understanding of payer environment to insights essential in formulating pricing and reimbursement strategies.
Our insights are carried forward to help our clients make informed decisions on market entry and clinical trial planning.
We bring to market the products that are on the verge of commercialization.
We identify the right target, devise optimized pricing scheme and develop tailored marketing plans to maximize chances of success.
what we do
Business Planning & Opportunity Assessment
We develop a long-list of prospective partners and prioritize them by the commercial and technical fit to our client’s clinical assets.
In parallel, we verify client data and assist in preparing pitching deliverables.
We lead partnership development activities and coordinate communication between prospective partners and our clients.
For promising partners, we develop an approach strategy based on our relationships and knowledge of the company.
Deal Structuring & Negotiation
We support negotiations of non-binding term sheets and coordinate final negotiations and deal completion.
Upon request, our experienced professionals lead the negotiation process from end-to-end.
what we do
With our combination of clinical, financial and operational experience,
we scout the globe for potential investment opportunities that address unmet medical needs.
Our focus is investing in promising pharmaceuticals and medical device companies built on technical and medical breakthroughs,
those which an infusion of capital and strategic guidance will greatly enhance chances of success.
Once investment is made, our professionals work intimately with portfolio companies,
to assure they achieve growth objectives and accelerate the delivery of new medical breakthroughs to patients.
behind the vision
Our unique blend of professionals from global top-notch consultancies and leading biopharma corporations
bring a balance of expertise that help companies realize full potential and get ahead of the curve.
Our team’s combination of managerial, operational and financial expertise has assisted foster some of today’s
most successful healthcare companies.
Chief Executive Officer
Brian is Founder and CEO at
Myriad Life Sciences with extensive
experience in consulting, business
development and intellectual property
Daniel is Director at Myriad Life
Sciences with more than 15 years of
experience in the Life Sciences and
Sung Hoon Byun,
Sung Hoon is Director at Myriad Life Sciences
and oversees the full range of service
offerings within the Life Sciences and
Hyungkoo is Associate Director at
Myriad Life Sciences leading a team of
professionals to provide advisory services
to clients in the Life Sciences and
Chief Executive Officer
Brian is Founder and CEO at Myriad Life Sciences with extensive experience in consulting, business development and intellectual property management.
Brian has played integral role in leading numerous drug valuation and global licensing deals for various multinational bio and pharmaceuticals companies.
Before founding Myriad Life Sciences, Brain led Intellectual Property and Sciences Group at Thomson Reuters.
Brian holds a B.A. from Sogang University.
Daniel is Director at Myriad Life Sciences with more than 15 years of experience in the Life Sciences and Healthcare industry.
Previously, Daniel was a Director of a global pharmaceutical company where his primary focus was drug valuation and has successfully led numerous licensing in/out deals for a number of leading pharmaceutical companies.
Prior to that, Daniel was Business Development Manager at Korea Drug Development Fund, and Manager of Global Information Services at Thomson Reuters.
Daniel holds a M.B.A. from the Kelley School of Business at Indiana University.
Sung Hoon Byun,
Sung Hoon is Director at Myriad Life Sciences and oversees the full range of service offerings within the Life Sciences and Healthcare industry.
Recently Sung Hoon has conducted drug valuation and formed commercialization strategies for conglomerate pharmaceuticals, the Korean Drug Development Fund,
and National OncoVenture.
Before joining Myriad Life Sciences, Sung Hoon was Manager at Deloitte Consulting Strategy Group, In-house Consultant at a leading conglomerate, and Manager at a leading
domestic biosimilar company.
Sung Hoon received a Bachelor of Science in Biomedical Engineering from Yonsei University.
Hyungkoo is Associate Director at Myriad Life Sciences, with extensive experience in business development, financial evaluation and deal execution within biopharma industry
At Myriad, Hyungkoo has successfully led numerous engagements to support companies maximize the commercial value of their innovations. His expertise includes market assessment, asset valuation, partnering and licensing support across difference therapeutic areas.
Prior to Myriad Life Sciences, Hyungkoo worked at Deloitte Consulting Strategy Group, where he served array of pharmaceutical and medical device clients with focus on strategic planning, due diligence and commercialization.
Hyungkoo received B.S. in Finance from McIntire School of Commerce at the University of Virginia.
Jae Hoon Chung, Ph.D.
Dr. Chung is current COO at Spark Biopharma. Previously he was a Researcher at Chong Kun Dang Pharmaceuticals, Researcher at C&C Laboratories and Specialist at Korea Drug Development Fund
Kyu Heun Kim, M.Sc, MBA
Kyu Heun is current Director of Global Market Access at Abbott Products Operations AG. Previously she worked at HIRA (Health Insurance Review & Assessment Service), Novartis AG and Amgen Inc.
Myung Hwan Cho, Ph.D.
Dr. Cho is current Professor of Economics at the University of Seoul. He received B.A. and M.A. in Economics at Seoul National University, and Ph.D. in Economics at Pennsylvania State University.
Yong Seok Choi, Ph.D.
Dr. Choi is current Professor at School of Pharmacy, Dankook University. He received M.A. in Pharmacy at Seoul National University, and Ph.D. in Chemistry at State University of New York at Buffalo.
Sung Joo Bae, Ph.D.
Dr. Bae is current Assistant Professor of Operations Management at Yonsei University. He received Ph.D. at MIT Sloan School of Management.
Mattias Obrecht, Attorney at Law, MBA
Mattias is current Director at Finma, a Swiss-based Financial Market Advisory